3-bromo-2-(2-chloro-6-fluorophenoxy)pyridine | 1167991-82-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-bromo-2-(2-chloro-6-fluorophenoxy)pyridine
• CAS: 1167991-82-3
• 化学式: C₁₁H₆BrClFNO
• 分子量: 302.53
• InChiKey: AMVHMSOBKAVEST-UHFFFAOYSA-N

物化性质

• 沸点：
  287.5±40.0 °C(Predicted)
• 密度：
  1.630±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-2-(2-chloro-6-fluorophenoxy)pyridine 、 N-Boc-哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 t-butoxide 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 甲苯 为溶剂， 生成 tert-butyl 4-(2-(2-chloro-6-fluorophenoxy)pyridin-3-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists

  摘要：

  Preclinical studies suggest that compounds with dual norepinephrine reuptake inhibitor (NRI) and 5-HT1A partial agonist properties may provide an important new therapeutic approach to ADHD, depression, and anxiety. Reported herein is the discovery of a novel chemical series with a favorable NRI and 5-HT1A partial agonist pharmacological pro. le as well as excellent selectivity for the norepinephrine transporter over the dopamine transporter. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.023
• 作为产物：
  描述：

  3-溴-2-氯吡啶 、 2-氯-6-氟苯酚 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以80%的产率得到3-bromo-2-(2-chloro-6-fluorophenoxy)pyridine
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists

  摘要：

  Compounds with combined norepinephrine reuptake inhibitor (NRI) and serotonin 1A (5-HT1A) partial agonist pharmacology may offer a new therapeutic approach for treating symptoms of neuropsychiatric disorders including ADHD, depression, and anxiety. Herein we describe the design and optimization of novel chemical matter that exhibits favorable dual NRI and 5-HT1A partial agonist activity. Lead compounds in this series were found to be devoid of activity at the dopamine transporter and were shown to be brain penetrant with high receptor occupancy. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.066

文献信息

• [EN] PHENOXY-PYRIDYL DERIVATIVES<br/>[FR] DÉRIVÉS PHÉNOXY-PYRIDYLÉS
  申请人：PFIZER

  公开号：WO2009081259A1

  公开（公告）日：2009-07-02

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  披露了化合物及化合物的药物可接受盐，其中化合物具有本说明书中定义的式(I)的结构。还披露了相应的药物组合物、治疗方法、合成方法和中间体。